America’s Blood Centers and its members are working closely with the U.S. Food and Drug Administration (FDA) to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.
While COVID-19 currently has no proven treatment, it is possible that convalescent plasma, a component of blood from patients that have recovered from COVID-19, that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19), may provide passive immunity for certain COVID-19 patients.
What is convalescent plasma?
Responding to the unprecedented challenge fighting coronavirus disease 2019 (COVID-19), a national effort is underway to collect and provide convalescent plasma to patients in need across the country. Plasma from recovered COVID-19 patients contains antibodies that may help fight the disease. The experimental treatment is approved by the U.S. Food and Drug Administration (FDA) to be used on an emergency basis. Critically ill patients who meet the FDA criteria to receive this therapy can be treated for life-threatening COVID-19. The entire blood community is working closely with the FDA to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.
Who is eligible to donate convalescent plasma for COVID-19 patients?
Individuals may be eligible to donate convalescent plasma if they had previously tested positive for COVID-19 and have been completely symptom free for at least 14 days and meet all standard FDA blood donation requirements.
Individuals who believe they may qualify to donate convalescent plasma should contact their local blood center or physician to determine their eligibility. Blood centers do not test individuals for COVID-19 and individuals should not go to a blood center if they are feeling ill.
I am a physician and/or hospital, where can I learn more?
Physicians and hospitals can learn more by visiting the FDA website on convalescent plasma emergency use.